EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative Cost‐Effectiveness of First‐Line Immunotherapy‐Based Regimens for Advanced Triple‐Negative Breast Cancer

Xiaoyue Sun, Xinyi Chen, Fandi Zhang, Xin Wu, Lei Liu, Jing Jing, Yuli Luo, Jiaqi Han, Jie Lan

Journal of Evidence-Based Medicine · 2026

DOI: 10.1111/jebm.70184 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Evidence-Based Medicine, 2026. Verfasst von Xiaoyue Sun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center,…. Hauptthemen laut MEDLINE: Immunotherapy, Triple Negative Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project of China, Sichuan Science and Technology Program, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Several first‐line immunotherapy‐based regimens are available for patients with programmed death ligand 1 positive advanced or metastatic triple‐negative breast cancer, but their relative economic value in China remains uncertain. This study evaluated selected regimens from the perspective of the Chinese healthcare system.

Methods

We developed an exploratory cross‐trial partitioned survival model using survival data from the IMpassion130, KEYNOTE‐355, TORCHLIGHT, and ASCENT‐04 Phase III trials, with utility and cost inputs from published sources and the Chinese healthcare setting. Outcomes included total costs, life‐years (LYs), quality‐adjusted life‐years (QALYs), and incremental cost‐utility ratios. Pairwise comparisons used a willingness‐to‐pay threshold of USD 43,333 per QALY.

Results

Pembrolizumab plus Sacituzumab Govitecan yielded the most LYs and QALYs, but at the highest cost. Toripalimab plus chemotherapy had the lowest cost, produced health outcomes similar to those of Pembrolizumab plus chemotherapy, and had the most favorable economic profile at the prespecified threshold. Pembrolizumab plus chemotherapy was cost‐effective versus Atezolizumab plus chemotherapy. Pembrolizumab plus Sacituzumab Govitecan was not cost‐effective, as its limited incremental benefit did not offset its substantially higher cost. Sensitivity analyses generally supported the base‐case findings.

Conclusions

Among the regimens evaluated, Toripalimab plus chemotherapy provided the most favorable balance between costs and health outcomes in China. Pembrolizumab plus chemotherapy also offered reasonable economic value versus Atezolizumab plus chemotherapy, whereas the value of Pembrolizumab plus Sacituzumab Govitecan was constrained by its high acquisition cost.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyTriple Negative Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCost-Benefit AnalysisHumansCost-Effectiveness AnalysisFemaleAntibodies, Monoclonal, HumanizedQuality-Adjusted Life YearsChinaAntineoplastic Agents, Immunological

Stichwörter der Autor:innen

advanced triple‐negative breast cancerantibody‐drug conjugatechemotherapycost‐effectivenessimmunotherapy

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Institute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China.
  • Tianfu Jincheng Laboratory, Chengdu, China.
  • Division of Head and Neck Tumor Multimodality Treatment, Cancer Center, West China School of Medicine and West China Hospital, Sichuan University, Chengdu, China.
  • Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
  • Nephrology Department, Yan'an Hospital of Kunming City, Kunming, China.
  • Laboratory of Liquid Biopsy and Single Cell Research, West China Hospital, Sichuan University, Chengdu, China.

Förderung

  • Noncommunicable Chronic Diseases-National Science and Technology Major Project of China
  • Sichuan Science and Technology Program
  • National Natural Science Foundation of China
  • Tianfu Jincheng Laboratory

Zitieren

APA

Sun, X., Chen, X., Zhang, F., Wu, X., Liu, L., Jing, J., Luo, Y., Han, J., & Lan, J. (2026). Comparative Cost‐Effectiveness of First‐Line Immunotherapy‐Based Regimens for Advanced Triple‐Negative Breast Cancer. Journal of Evidence-Based Medicine. https://doi.org/10.1111/jebm.70184

Vancouver

Sun X, Chen X, Zhang F, Wu X, Liu L, Jing J, et al. Comparative Cost‐Effectiveness of First‐Line Immunotherapy‐Based Regimens for Advanced Triple‐Negative Breast Cancer. Journal of Evidence-Based Medicine. 2026. doi:10.1111/jebm.70184

BibTeX
@article{Sun2026,
  author = {Sun, Xiaoyue and Chen, Xinyi and Zhang, Fandi and Wu, Xin and Liu, Lei and Jing, Jing and Luo, Yuli and Han, Jiaqi and Lan, Jie},
  title = {Comparative Cost‐Effectiveness of First‐Line Immunotherapy‐Based Regimens for Advanced Triple‐Negative Breast Cancer},
  journal = {Journal of Evidence-Based Medicine},
  year = {2026},
  doi = {10.1111/jebm.70184}
}
Kostenlos starten →